PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Müller, T.D. ; Finan, B.* ; Bloom, S.R.* ; D'Alessio, D.* ; Drucker, D.J.* ; Flatt, P.R.* ; Fritsche, A. ; Gribble, F.* ; Grill, H.J.* ; Habener, J.F.* ; Holst, J.J.* ; Langhans, W.* ; Meier, J.J.* ; Nauck, M.A.* ; Perez-Tilve, D.* ; Pocai, A.* ; Reimann, F.* ; Sandoval, D.A.* ; Schwartz, T.W.* ; Seeley, R.J.* ; Stemmer, K. ; Tang-Christensen, M.* ; Woods, S.C.* ; DiMarchi, R.D.* ; Tschöp, M.H.

Glucagon-like peptide 1 (GLP-1).

Mol. Metab. 30, 72-130 (2019)
Publ. Version/Full Text DOI
Open Access Gold
Creative Commons Lizenzvertrag
Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity. Scope of review: In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. Major conclusions: Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone. The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
6.181
1.435
527
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Review
Keywords Diabetes ; Glp-1 ; Glucagon ; Incretin ; Insulin ; Obesity
Language english
Publication Year 2019
HGF-reported in Year 2019
ISSN (print) / ISBN 2212-8778
e-ISSN 2212-8778
Journal Molecular Metabolism
Quellenangaben Volume: 30, Issue: , Pages: 72-130 Article Number: , Supplement: ,
Publisher Elsevier
Publishing Place Amsterdam
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Obesity (IDO)
Institute of Diabetes Research and Metabolic Diseases (IDM)
POF-Topic(s) 30201 - Metabolic Health
90000 - German Center for Diabetes Research
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-502200-001
G-501900-221
G-502400-001
DOI 10.1016/j.molmet.2019.09.010
Scopus ID 85073166351
Erfassungsdatum 2019-10-21
[➜Report correction]